In short
ETX-19477 is a promising new drug currently being studied for patients with advanced solid tumors. This novel treatment works as a PARG inhibitor (Poly ADP-ribose glycohydrolase inhibitor), targeting a specific vulnerability in cancer cells related to DNA damage repair. The ongoing clinical trial is designed to evaluate how safe and effective ETX-19477 is for patients whose cancer has progressed after standard treatments. The study focuses on various types of cancer including breast, ovarian, prostate, endometrial, colorectal, and gastric cancers, with special attention to patients with certain genetic mutations like BRCA1 and BRCA2.
Key points
- ETX-19477 is a novel oral drug currently in clinical trials for patients with advanced solid tumors who have exhausted standard treatment options. The drug works by inhibiting PARG, an enzyme involved in DNA damage repair, targeting a specific vulnerability in cancer cells. The two-part clinical trial is evaluating the safety, how the drug moves through the body, and how effective it is against various cancer types including breast, ovarian, prostate, endometrial, and colorectal cancers. ETX-19477 exploits cancer cells' difficulty with DNA replication, potentially leading to cancer cell death while minimizing harm to healthy cells. Preliminary results will assess how well tumors respond to the treatment and how long these responses last.
At a glance
- Drug Name
- ETX-19477
- Drug Type
- PARG (Poly ADP-ribose glycohydrolase) inhibitor
- Administration
- Oral medication taken daily
- Study Design
- Two-part, open-label, multicenter, dose escalation and dose expansion study
- Target Conditions
- Advanced or metastatic solid tumors, including breast cancer (ER+), ovarian cancer, prostate cancer (castrate resistant), endometrial cancer, colorectal cancer, gastric cancer
- Genetic Focus
- Includes patients with BRCA1 and BRCA2 mutations
- Primary Outcomes
- Safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D)
- Secondary Outcomes
- Pharmacokinetic profile (Cmax, tmax, t1/2, AUC), anti-tumor activity (objective response rate, duration of response, disease control rate)
- Mechanism of Action
- Targets cancer-specific vulnerability by inhibiting DNA damage repair in cells with replication stress
- Clinical Trial Identifier
- NCT06395519
What is ETX-19477?
ETX-19477 is a new medication being studied for the treatment of advanced solid tumors. It is classified as a PARG inhibitor, which means it blocks an enzyme called Poly (ADP) ribose glycohydrolase (PARG). This medication is currently in clinical trials to evaluate how safe it is, how well it's tolerated by patients, and whether it shows promising anti-cancer activity.
Specifically, ETX-19477 is described as a novel reversible small molecule inhibitor of PARG. The term "reversible" means that the drug's effects can be undone when the medication is stopped, and "small molecule" refers to the size of the drug, which allows it to potentially reach targets inside cells more easily.
How ETX-19477 Works
Cancer cells often experience what scientists call replication stress. This is a condition where the process of copying DNA (which happens when cells divide) is slowed down or stalled, leading to damaged DNA accumulating in the cells. Normally, cells have mechanisms to repair this damage through a process called the DNA damage response (DDR).
The enzyme PARG plays an important role in this DNA repair process. When PARG is blocked (as ETX-19477 is designed to do), cancer cells accumulate more DNA damage in the form of single-strand breaks (SSBs) and double-strand breaks (DSBs). The cancer cells also have more difficulty repairing this damage.
When PARG is inhibited in cancer cells that are already experiencing replication stress, research has shown that these cells may:
- Stop multiplying
- Get stuck in certain phases of the cell division cycle (S or G2 phase)
- Undergo apoptosis (programmed cell death)
This effect can happen when PARG inhibitors are used alone or combined with other drugs that damage DNA or increase replication stress.
The research suggests that the replication stress response represents a vulnerability specific to cancer cells, which can be targeted by medications that inhibit PARG, like ETX-19477.
Conditions ETX-19477 May Treat
ETX-19477 is being studied for several types of advanced or metastatic solid tumors. Metastatic means that the cancer has spread from where it started to other parts of the body. Based on the clinical trial information, the following cancer types are included:
- Breast Cancer - specifically ER+ (estrogen receptor positive) breast cancer, which is a type of breast cancer that grows in response to the hormone estrogen
- Ovarian Cancer - including epithelial ovarian cancer, which starts in the cells that cover the surface of the ovary
- Prostate Cancer - specifically castrate-resistant prostate cancer, an advanced form that continues to grow even when the level of testosterone is reduced to very low levels
- Endometrial Cancer - cancer that begins in the lining of the uterus (womb)
- Colorectal Cancer - cancer that starts in the colon or rectum
- Gastric Cancer - cancer that begins in the stomach
The trial also specifically mentions patients with BRCA mutations (BRCA1, BRCA2). These are genetic mutations that affect the body's ability to repair DNA damage and are associated with increased risk of certain cancers, particularly breast and ovarian cancers.
Current Clinical Trial Design
The clinical trial for ETX-19477 (identified as NCT06395519) is designed as a two-part study:
Part 1: Dose Escalation
In this first phase, researchers are trying to find the right dose of ETX-19477. Participants are assigned to different dose levels to determine:
- The maximum tolerated dose (MTD) - the highest dose that doesn't cause unacceptable side effects
- The recommended Phase 2 dose (RP2D) - the dose that will be used in future larger studies
Part 2: Dose Expansion
Once the appropriate dose is determined in Part 1, more participants will receive ETX-19477 at this dose level. This helps researchers collect more data about the safety and effectiveness of the drug at the chosen dose.
This is an open-label study, which means both the researchers and participants know which treatment is being given. It is also multicenter, meaning it's being conducted at multiple hospitals or research centers.
Safety Monitoring and Outcomes
A primary goal of the trial is to assess the safety and tolerability of ETX-19477. Researchers are monitoring:
- Dose-limiting toxicities (DLTs) - side effects that are severe enough to prevent increasing the dose further
- Adverse events (AEs) - any unfavorable and unintended sign, symptom, or disease that develops during treatment
- ECG parameters - measurements of heart electrical activity to detect any cardiac effects
- Serious adverse events (SAEs) - adverse events that result in hospitalization, disability, or are life-threatening
How Effectiveness is Being Measured
The trial is assessing several ways to measure whether ETX-19477 is effective against cancer:
- Objective response rate (ORR) - the percentage of patients whose cancer shrinks or disappears after treatment
- Duration of response (DOR) - how long the response (cancer remaining smaller or gone) lasts
- Disease control rate (DCR) - the percentage of patients whose disease is controlled (stays the same, shrinks, or disappears)
These measurements are being assessed using standardized criteria called RECIST v1.1 (Response Evaluation Criteria in Solid Tumors), which is a set of rules used to determine whether tumors are responding to treatment.
The trial is also studying how ETX-19477 behaves in the body through:
- Pharmacokinetics (PK) - how the drug moves through the body, including:
- Maximum plasma concentration (Cmax) - the highest level of drug in the blood
- Time to maximum concentration (tmax) - how long it takes to reach the highest level
- Elimination half-life (t1/2) - how long it takes for half of the drug to be eliminated from the body
- Area Under the Curve (AUC) - a measure of the total exposure to the drug over time
- Clearance (CL) - how quickly the drug is removed from the body
- Volume of Distribution (Vd) - how widely the drug is distributed throughout the body
- Pharmacodynamics (PDx) - the effects of the drug on the body
How ETX-19477 is Administered
ETX-19477 is an oral medication, which means it is taken by mouth. According to the trial information, it is taken daily. This oral administration may be more convenient for patients compared to treatments that need to be given by injection or infusion.